Recombinant Canine Tumor Necrosis Factor-alpha/TNFSF2 (rCaTNF-alpha/TNFSF2)
VKSSSRTPSD KPVAHVVANP EAEGQLQWLS RRANALLANG VELTDNQLIV PSDGLYLIYS QVLFKGQGCP STHVLLTHTI SRFAVSYQTK VNLLSAIKSP CQRETPEGTE AKPWYEPIYL GGVFQLEKGD RLSAEINLPN YLDFAESGQV YFGIIAL
Approximately 17.3 kDa, a single non-glycosylated polypeptide chain containing 157 amino acids.
Fully biologically active when compared to standard. The ED50 as determined by a cytotoxicity assay using murine L929 cells is less than 1.0 ng/ml, corresponding to a specific activity of > 1.0 × 106 IU/mg in the presence of actinomycin D.
Sterile Filtered White lyophilized (freeze-dried) powder.
Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4.
Less than 1 EU/ug of rCaTNF-alpha as determined by LAL method.
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
> 95 % by SDS-PAGE and HPLC analyses.
Recombinant Canine Tumor Necrosis Factor-alpha/TNFSF2是ChemWhat品牌授权产品并通过沃尔森销售，下面是ChemWhat上的该产品链接 Recombinant Canine Tumor Necrosis Factor-alpha/TNFSF2 (rCaTNF-alpha/TNFSF2)